SCHEMBL21749512

SCHEMBL21749512

CC(C)c1cc(Oc2c(Cl)cc(-c3noc(=O)[nH]3)cc2Cl)nn(C)c1=O

nearest known ligand 0.69

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
THRB P10828 19/20 0.69
THRA P10827 19/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21749431 0.82 THRB (1.00) THRBTHRA
SCHEMBL21769749 0.82 THRB (1.00) THRBTHRA
SCHEMBL21749499 0.82 THRB (0.72) THRBTHRA
SCHEMBL31664947 0.82 THRB (0.72) THRBTHRA
SCHEMBL21749478 0.81 THRB (1.00) THRBTHRA
SCHEMBL21749469 0.81 THRB (1.00) THRBTHRA
SCHEMBL21749351 0.81 THRA (1.00) THRBTHRA
SCHEMBL21749521 0.81 THRB (1.00) THRBTHRA
SCHEMBL21749549 0.79 THRA (1.00) THRBTHRA
SCHEMBL32675684 0.78 THRA (0.63) THRBTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112805005-B Thyroxine receptor beta agonist compounds 拓臻股份有限公司 2026-05-12 CN disclosed
US-20250236615-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns, Inc. 2025-07-24 US disclosed
US-20230226038-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS VIKING THERAPEUTICS, INC. 2023-07-20 US disclosed
EP-3840755-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns, Inc. (US) 2021-06-30 EP disclosed
CN-112805005-A Thyroxine receptor beta agonist compounds 拓臻股份有限公司 2021-05-14 CN disclosed
US-10800767-B2 Thyroid hormone receptor beta agonist compounds Terns, Inc. (US) 2020-10-13 US disclosed
US-10800767-B2 Thyroid hormone receptor beta agonist compounds Terns, Inc. (US) 2020-10-13 US disclosed
WO-2020041741-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns, Inc. (US) 2020-02-27 WO disclosed
US-20200062742-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns, Inc. 2020-02-27 US disclosed
US-20200062742-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns, Inc. 2020-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062742-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS THRB, THRA, TSHR THRB 1/4885THRA 2/4885
US-20230226038-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS FABP1, SLC10A1, LIPC THRB 19/4885THRA 25/4885
US-20250236615-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS THRB, THRA, TSHR THRB 1/4885THRA 2/4885
US-10800767-B2 Thyroid hormone receptor beta agonist compounds THRB, THRA, TSHR THRB 1/4885THRA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.